Daily Roundup

SLC.ASX SIQ.ASX AHC.ASX DSE.ASX MAP.ASX

Superloop Achieves Milestone 3 of Origin Contract

Superloop Limited (ASX:SLC) has achieved a significant milestone in its exclusive six-year contract with Origin Energy Retail Ltd. The company has now onboarded over 200,000 Origin broadband subscribers onto its network, marking the achievement of Milestone 3 under the contract. Superloop's purpose is to enable better internet for Australian homes and businesses, and this milestone demonstrates the company's progress in delivering on that mission.

Smartgroup Presents 2025 AGM Materials

Smartgroup Corporation Ltd (ASX: SIQ) has presented its 2025 Annual General Meeting materials, highlighting the company's strong financial performance in 2024. Smartgroup reported revenue growth of 22%, EBITDA growth of 18%, and NPATA growth of 15%, driven by record customer numbers in salary packaging, novated leases, and fleet vehicles. The company also made significant progress on its strategic priorities, including brand consolidation and digital investments to enhance the customer experience and drive future growth.

Austco Healthcare Secures $2.1M Contract at Toronto Western Hospital

Austco Healthcare Limited (ASX: AHC) has secured a AUD $2.1 million contract to supply and implement its Tacera nurse call platform for a new patient tower at Toronto Western Hospital in Canada. This project is part of a $1 billion healthcare investment by the Province of Ontario and will see Austco's solution integrate with the hospital's systems and building management, facilitating real-time clinical communication and enhancing patient safety.

Dropsuite Scheme of Arrangement Becomes Legally Effective

Dropsuite Limited (ASX:DSE) has announced that its proposed acquisition by NinjaOne Australia Pty Ltd via a Scheme of Arrangement has become legally effective. As a result, Dropsuite shares will be suspended from trading on the ASX, and shareholders will receive $5.90 cash per share on the implementation date, currently expected to be 30 May 2025.

Microba Life Sciences Announces Landmark GI Study Results

Microba Life Sciences Ltd (ASX: MAP) has announced preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results. The study found that 71.4% of the reports identified actionable results, with 41.9% showing abnormal microbiome markers linked to gastrointestinal health. Additionally, 65.5% of patients who received MetaXplore-guided care reported health improvements. These results highlight the clinical value of Microba's test in advancing outcomes for patients with chronic lower gastrointestinal disorders.